HUA MEDICINE-B (02552) granted a total of 20 million share purchase rights.
Hua Ling Pharmaceuticals Group-B (02552) announced that on November 28, 2025, the company granted stock options to three executive directors and 71 employees in accordance with the company's stock option plan approved and adopted on August 26, 2018, and effective on September 14, 2018. However, the grantee must accept the stock options before they can be exercised. The stock options grant the grantee the right to subscribe for a total of 20 million new shares in the company's capital, with a par value of $0.001 per share.
HUA MEDICINE-B(02552) announced that on November 28, 2025, the company granted stock options to three executive directors and 71 employees in accordance with the company's share option scheme approved and adopted on August 26, 2018, and effective from September 14, 2018. However, the grant recipients must accept the options before they can be exercised. The stock options grant the recipients the right to subscribe for a total of 20 million new shares of the company's stock, with a par value of $0.001 per share.
Related Articles

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


